Biogen (BIIB)
(Delayed Data from NSDQ)
$204.76 USD
-0.06 (-0.03%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $204.61 -0.15 (-0.07%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth D Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$204.76 USD
-0.06 (-0.03%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $204.61 -0.15 (-0.07%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth D Momentum C VGM
Zacks News
Drug/Biotech Stock Q3 Earnings Due on Oct 29: MRK, PFE & More
by Zacks Equity Research
Four drug/biotech stocks are scheduled to release third-quarter results on Oct 29. Let's see how these companies are placed before their earnings call.
The Zacks Analyst Blog Highlights: Biogen, Vertex, Amgen, Alexion and Achillion Pharmaceuticals
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Biogen, Vertex, Amgen, Alexion and Achillion Pharmaceuticals
Alkermes' (ALKS) Earnings and Sales Beat Estimates in Q3
by Zacks Equity Research
Alkermes (ALKS) beats estimates in the third quarter of 2019. Its proprietary products, especially Aristada, drive revenues.
Biotech ETFs Surge on a Flurry of Positive News
by Sweta Killa
The biotech sector got a boost over the past week from a flurry of positive news including trial results and deal activities.
Biotech Stock Roundup: BIIB Up on AD Data, ALXN to Buy ACHN & Other Pipeline Updates
by Zacks Equity Research
Key highlights of the past week include acquisition news, and regulatory and pipeline updates.
Earnings Data Deluge
by Zacks Equity Research
Earnings Data Deluge
Biogen (BIIB) Up 40% on Alzheimer's Drug & More
by Mark Vickery
This is about as "game changer" as a drug can get, at least in the early stages.
Biogen (BIIB) Beats on Q3 Earnings, Eyes FDA Nod for Aducanumab
by Zacks Equity Research
Biogen (BIIB) beats estimates for both earnings and sales in the third quarter. It is set to pursue FDA approval of aducanumab. Shares skyrocket in pre-market trading.
Biogen (BIIB) Q3 Earnings & Sales Beat Estimates
by Zacks Equity Research
Biogen (BIIB) beats estimates for both earnings and sales in the third quarter. It is set to pursue FDA approval of aducanumab. Shares skyrocket in pre-market trading.
Earnings Surprise May Lift Stocks: Buy These Growth ETFs
by Sweta Killa
Market participants are betting on the record-high U.S. indices as about 120 S&P 500 companies are scheduled to release their results this week.
Biogen (BIIB) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Biogen's (BIIB) MS franchise sales are expected to have been soft in the third quarter of 2019. Spinraza U.S. sales are expected to have been supported by continued patient growth
Biogen Strengthens MS & SMA Portfolio as Competition Lurks
by Zacks Equity Research
Biogen strengthens existing efforts in multiple sclerosis and spinal muscular atrophy while making efforts to foray into other neuroscience areas. However, MS is a competitive space. Spinraza may soon face competition.
The Zacks Analyst Blog Highlights: Verizon Communications, PepsiCo, Biogen, Bank of New York ??? Mellon and Cerner
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Verizon Communications, PepsiCo, Biogen, Bank of New York ??? Mellon and Cerner
Top Stock Reports for Verizon, PepsiCo & Biogen
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Verizon Communications (VZ), PepsiCo (PEP) and Biogen (BIIB).
Biotech Stock Roundup: Pipeline Updates From REGN, BIIB, AMGN and More
by Zacks Equity Research
Key highlights of the past week include regulatory and pipeline updates, licensing deals, and more.
Biogen's Two MS Drugs Get CHMP Nod for Use in Pregnancy
by Zacks Equity Research
Biogen (BIIB) gets CHMP's recommendation to remove pregnancy contraindications from labels of interferon beta treatments, including Plegridy and Avonex
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
by Sweta Killa
Sector ETF report for PBE
Biogen's New Study to Test Higher Dose of SMA Drug Spinraza
by Zacks Equity Research
Biogen (BIIB) starts a DEVOTE study to investigate whether a higher dose of Spinraza can provide greater efficacy for treating patients with spinal muscular atrophy.
Alexion (ALXN) Down on News of CFO Clancy's Departure in 2019
by Zacks Equity Research
Alexion's (ALXN) shares decline, following the news of the departure of its current chief financial officer, Paul Clancy.
Biotech Stock Roundup: BIIB Halts AD Study, AMGN Posts Positive MM Drug Data & More
by Zacks Equity Research
Key highlights of the past week include regulatory and pipeline updates, acquisition deals, and more.
Roche's Gazyva Now a Breakthrough Therapy for Lupus Nephritis
by Zacks Equity Research
Roche's (RHHBY) lymphoma drug, Gazyva, obtains Breakthrough Therapy designation in the United States for lupus nephritis.
The Zacks Analyst Blog Highlights: Biogen, Crocs, Casey's General Stores and Clean Harbors
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Biogen, Crocs, Casey's General Stores and Clean Harbors
Biogen Stops Late-Stage Studies on Alzheimer's Candidate
by Zacks Equity Research
Biogen (BIIB) and its Japanese partner, Eisai receive another setback as they discontinue two late-stage studies evaluating elenbecestat in patients with Alzheimer's disease.
What September Doldrums? Here's Why Stocks Are Moving Higher
by Tirthankar Chakraborty
From ECB stimulus to trade optimism, all are helping stocks eke out gains. And let's admit that recession may be coming, but it isn't around the corner.
Top 5 ROE Stocks to Profit as Sino-US Trade Tensions Abate
by Supriyo Bose
ROE helps investors distinguish profit-generating companies from profit burners and is useful in determining the financial health of a company.